Please assess the completion status of the following clinical trial:

Trial Title: Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented metastatic or recurrent gastric adenocarcinoma including adenocarcinoma of the gastro-esophageal junction~* Age 18 to 74 years old~* Performance status (ECOG scale) 0-2~* No significant problems for oral intake and drug administration~* At least one measurable or evaluable disease defined by RECIST~* Adequate bone marrow function (ANC ≥ 1,500/uL, Platelet ≥ 100,000/ uL, Hb ≥ 9.0 g/dl)~* Adequate renal function: serum creatinine ≤ UNL (if serum creatinine \> UNL, creatinine clearance should be ≥ 60 mL/min)~* Adequate hepatic function (Total bilirubin \< 2 x UNL and AST/ALT levels \< 3 x UNL without liver metastasis,total bilirubin \< 3x ULN and AST/ALT levels \< 5 x UNL with liver metastasis)~* Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study) and cisplatin was not used before~* Patients should sign a written informed consent before study entry~Exclusion Criteria:~* Tumor type other than adenocarcinoma~* Previously exposed to any fluropymidine within 6 months before the study~* Previously exposed to Platinum therapy regardless of its period and/or duration~* Microscopic residual disease only after noncurative gastrectomy with R1 resection (resection margin positive)~* Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence)~* Prior radiotherapy was administered to target lesions selected for this study, or radiotherapy to the non-target lesions has been completed within 4 weeks before randomization~* Presence of CNS metastasis~* Major surgery within 4 weeks before initiation of study treatment or lack of complete recovery from the effects of major surgery (patient received curative operation or RFA for metastatic disease)~* Serious illness or medical conditions:~  * Congestive heart failure (NYHA class III or IV)~ * Unstable angina or myocardial infarction within the past 12 months~ * Significant arrhythmias requiring medication and conduction abnormality such as over 2nd degree AV block~ * Uncontrolled hypertension~ * Hepatic cirrhosis (≥ Child class B)~ * Interstitial pneumonia~ * Pulmonary adenomatosis~ * Psychiatric disorder that may interfere with protocol compliance~ * Unstable diabetes mellitus~ * Uncontrolled ascites or pleural effusion~ * Active infection~* Receiving a concomitant treatment interacting with S-1 or cisplatin:~  * Flucytosine (a fluorinated pyrimidine antifungal agent)~ * Antivirals such as sorivudine, ramivudine, brivudine or other chemically related agents, warfarin, phenprocoumon, phenytoin, allopurinol~* Pregnant or lactating woman~* Women of child bearing potential not using a contraceptive method~* Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential~* Any patients judged by the investigator to be unfit to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 3 weekly regimen of S-1 and cisplatin (Type: ACTIVE_COMPARATOR): None
- 5 weekly regimen of S-1 and cisplatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).